Abstract
Although tremendous effort has been made over the past century to treat cancer effectively, the pace of drug development is far behind the increasing rate of cancer incidence and mortality. There are two major hurdles in anticancer drug development: dose-limiting toxic side effects that reduce either drug effectiveness or the quality of life of patients and complicated drug development processes that are costly and time consuming. Drug repositioning has recently gained increasing attention among cancer researchers as this approach utilizes existing drugs and is significantly cost- and time-effective. Existing drugs, particularly non-cancer drugs, have favorable safety profiles in humans and serve as an ever-increasing source for new anticancer drug discovery. Here we review the recent examples of drug repositioning of existing non-cancer drugs for preclinical and clinical introductions of cancer therapy.
Keywords: Cancer, Disulfiram, Doxycycline, Drug repositioning, Existing drugs, Mebendazole, Pyrvinium pamoate, Triclosan.
Current Topics in Medicinal Chemistry
Title:Revisiting Non-Cancer Drugs for Cancer Therapy
Volume: 16 Issue: 19
Author(s): Eun Ju Yang, Changjie Wu, Yifan Liu, Junfang Lv and Joong Sup Shim
Affiliation:
Keywords: Cancer, Disulfiram, Doxycycline, Drug repositioning, Existing drugs, Mebendazole, Pyrvinium pamoate, Triclosan.
Abstract: Although tremendous effort has been made over the past century to treat cancer effectively, the pace of drug development is far behind the increasing rate of cancer incidence and mortality. There are two major hurdles in anticancer drug development: dose-limiting toxic side effects that reduce either drug effectiveness or the quality of life of patients and complicated drug development processes that are costly and time consuming. Drug repositioning has recently gained increasing attention among cancer researchers as this approach utilizes existing drugs and is significantly cost- and time-effective. Existing drugs, particularly non-cancer drugs, have favorable safety profiles in humans and serve as an ever-increasing source for new anticancer drug discovery. Here we review the recent examples of drug repositioning of existing non-cancer drugs for preclinical and clinical introductions of cancer therapy.
Export Options
About this article
Cite this article as:
Ju Yang Eun, Wu Changjie, Liu Yifan, Lv Junfang and Sup Shim Joong, Revisiting Non-Cancer Drugs for Cancer Therapy, Current Topics in Medicinal Chemistry 2016; 16 (19) . https://dx.doi.org/10.2174/1568026616666160216154441
DOI https://dx.doi.org/10.2174/1568026616666160216154441 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Indole Derivatives as Anticancer Agents for Breast Cancer Therapy: A Review
Anti-Cancer Agents in Medicinal Chemistry Relaxin-Like Peptides in Neoplastic Lesions
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Identification of Leads from Marine Seaweeds against Human β-tubulin
Letters in Drug Design & Discovery MicroRNA Therapeutics: the Next Magic Bullet?
Mini-Reviews in Medicinal Chemistry Potential of Gene Therapy for the Treatment of Pituitary Tumors
Current Gene Therapy Emerging Roles of P2X Receptors in Cancer
Current Medicinal Chemistry Recent Advances in the Synthesis and Development of Curcumin, its Combinations and Formulations and Curcumin-like Compounds as Anti-infective Agents
Current Medicinal Chemistry Dynamic Crosstalk between GlcNAcylation and Phosphorylation: Roles in Signaling, Transcription and Human Disease
Current Signal Transduction Therapy Is the Epithelial-to-Mesenchymal Transition Clinically Relevant for the Cancer Patient?
Current Pharmaceutical Biotechnology Cancer and Stem Cells
Current Cancer Therapy Reviews Chronobiology of the Neuroimmunoendocrine System and Aging
Current Pharmaceutical Design Stem Cell Therapy for Ischaemic Stroke: Translation from Preclinical Studies to Clinical Treatment
CNS & Neurological Disorders - Drug Targets What Makes Y Family Pols Potential Candidates for Molecular Targeted Therapies and Novel Biotechnological Applications
Current Molecular Medicine Exploiting Novel Cell Cycle Targets in the Development of Anticancer Agents
Current Cancer Drug Targets Cystine Dimethyl Ester Induces Apoptosis Through Regulation of PKC-δ and PKC-ε in Prostate Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Phosphorylation Processes Controlling Aromatase Activity in Br east Cancer: An Update
Mini-Reviews in Medicinal Chemistry Serum Carboxypeptidase N1 Serves as a Potential Biomarker Complementing CA15-3 for Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry Molecular Phenotype of CXCL12β 3UTR G801A Polymorphism (rs1801157) Associated to HIV-1 Disease Progression
Current HIV Research Clinical Development of Inhibitors of the Insulin-like Growth Factor Receptor in Oncology
Current Drug Targets Cancer Chemoprevention Drug Targets
Current Drug Targets